Resaphene Suisse AG: Charité Ethics Committee in Berlin Approves Study on Tinniwell Tinnitus Therapy
ROGGWIL,
The double-blind study has the same design as a first clinical user observation by Dr. med.
If the study is successfully completed, the management of Resaphene assumes the participation of further institutional investors or the sale of intellectual property to a hearing aid manufacturer as part of an exit strategy of the previous shareholders. No binding contracts have yet been concluded for this.
++ About
Language: |
English |
||
Company: |
|
||
Rütistrasse 8b |
|||
9325 Roggwil |
|||
|
|||
Phone: |
0041714500668 |
||
E-mail: |
|||
Internet: |
|||
ISIN: |
CH0367465439 |
||
Listed: |
Foreign Exchange(s) |
||
EQS News ID: |
957405 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200121005459/en/
Investor Relations contact:
Mrs.
[email protected]
Source:
Stauber pitches reelection bid to carpenters
Fitch Upgrades Kemper’s Key Financial Strength Ratings
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News